Filing Details
- Accession Number:
- 0001447362-20-000261
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-16 16:14:40
- Reporting Period:
- 2020-11-12
- Accepted Time:
- 2020-11-16 16:14:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1447362 | Castle Biosciences Inc | CSTL | Services-Medical Laboratories (8071) | 770701774 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1782815 | Frank Stokes | C/O Castle Biosciences, Inc. 820 S. Friendswood Drive, Suite 201 Friendswood TX 77546 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-11-12 | 13,000 | $2.39 | 14,886 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-12 | 5,079 | $50.20 | 9,807 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-12 | 2,121 | $51.19 | 7,686 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-12 | 5,731 | $52.20 | 1,955 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-12 | 69 | $52.96 | 1,886 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-11-13 | 13,000 | $2.39 | 14,886 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-13 | 12,167 | $50.41 | 2,719 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-13 | 633 | $51.30 | 2,086 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-13 | 200 | $52.04 | 1,886 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2020-11-12 | 13,000 | $0.00 | 13,000 | $2.39 |
| Common Stock | Stock option (right to buy) | Disposition | 2020-11-13 | 13,000 | $0.00 | 13,000 | $2.39 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 68,137 | 2028-05-09 | No | 4 | M | Direct | |
| 55,137 | 2028-05-09 | No | 4 | M | Direct |
Footnotes
- These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.
- This transaction was executed in multiple trades at prices ranging from $49.585 to $50.560, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $50.630 to $51.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $51.770 to $52.675, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $50.000 to $50.885, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $51.000 to $51.800, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $52.010 to $52.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
